Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 22 12 2022
accepted: 19 03 2023
medline: 5 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: epublish

Résumé

Ocular toxoplasmosis (OT) is caused by the parasite Toxoplasma gondii. OT is the leading cause of posterior uveitis globally; it is a recurrent disease that may result in visual impairment and blindness. This systematic review and meta-analysis aim to summarize and evaluate the risk factors for recurrences, visual impairment, and blindness described in the literature worldwide. We performed a systematic literature search in PubMed, Embase, VHL, Cochrane Library, Scopus, and DANS EASY Archive. All studies reporting patients with clinically and serologically confirmed OT presenting any clinical or paraclinical factor influencing recurrences, visual impairment, and blindness were included. Studies presenting secondary data, case reports, and case series were excluded. An initial selection was made by title and abstract, and then the studies were reviewed by full text where the eligible studies were selected. Then, the risk of bias was assessed through validated tools. Data were extracted using a validated extraction format. Qualitative synthesis and quantitative analysis were done. This study was registered on PROSPERO (CRD42022327836). Seventy two studies met the inclusion criteria. Fifty-three were summarized in the qualitative synthesis in three sections: clinical and environmental factors, parasite and host factors, and treatment-related factors. Of the 72 articles, 39 were included in the meta-analysis, of which 14 were conducted in South America, 13 in Europe, four in Asia, three multinational, two in North America and Central America, respectively, and only one in Africa. A total of 4,200 patients with OT were analyzed, mean age ranged from 7.3 to 65.1 year of age, with similar distribution by sex. The frequency of recurrences in patients with OT was 49% (95% CI 40%-58%), being more frequent in the South American population than in Europeans. Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR of 4.83 (95% CI; 2.72-8.59) for blindness, similar to having more than one recurrence that had an OR of 3.18 (95% CI; 1.59-6.38). Finally, the prophylactic therapy with Trimethoprim/Sulfamethoxazole versus the placebo showed a protective factor of 83% during the first year and 87% in the second year after treatment. Our Systematic Review showed that clinical factors such as being older than 40 years, patients with de novo OT lesions or with less than one year after the first episode, macular area involvement, lesions greater than 1 disc diameter, congenital toxoplasmosis, and bilateral compromise had more risk of recurrences. Also, environmental and parasite factors such as precipitations, geographical region where the infection is acquired, and more virulent strains confer greater risk of recurrences. Therefore, patients with the above mentioned clinical, environmental, and parasite factors could benefit from using prophylactic therapy.

Sections du résumé

BACKGROUND
Ocular toxoplasmosis (OT) is caused by the parasite Toxoplasma gondii. OT is the leading cause of posterior uveitis globally; it is a recurrent disease that may result in visual impairment and blindness. This systematic review and meta-analysis aim to summarize and evaluate the risk factors for recurrences, visual impairment, and blindness described in the literature worldwide.
METHODS AND FINDINGS
We performed a systematic literature search in PubMed, Embase, VHL, Cochrane Library, Scopus, and DANS EASY Archive. All studies reporting patients with clinically and serologically confirmed OT presenting any clinical or paraclinical factor influencing recurrences, visual impairment, and blindness were included. Studies presenting secondary data, case reports, and case series were excluded. An initial selection was made by title and abstract, and then the studies were reviewed by full text where the eligible studies were selected. Then, the risk of bias was assessed through validated tools. Data were extracted using a validated extraction format. Qualitative synthesis and quantitative analysis were done. This study was registered on PROSPERO (CRD42022327836).
RESULTS
Seventy two studies met the inclusion criteria. Fifty-three were summarized in the qualitative synthesis in three sections: clinical and environmental factors, parasite and host factors, and treatment-related factors. Of the 72 articles, 39 were included in the meta-analysis, of which 14 were conducted in South America, 13 in Europe, four in Asia, three multinational, two in North America and Central America, respectively, and only one in Africa. A total of 4,200 patients with OT were analyzed, mean age ranged from 7.3 to 65.1 year of age, with similar distribution by sex. The frequency of recurrences in patients with OT was 49% (95% CI 40%-58%), being more frequent in the South American population than in Europeans. Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR of 4.83 (95% CI; 2.72-8.59) for blindness, similar to having more than one recurrence that had an OR of 3.18 (95% CI; 1.59-6.38). Finally, the prophylactic therapy with Trimethoprim/Sulfamethoxazole versus the placebo showed a protective factor of 83% during the first year and 87% in the second year after treatment.
CONCLUSION
Our Systematic Review showed that clinical factors such as being older than 40 years, patients with de novo OT lesions or with less than one year after the first episode, macular area involvement, lesions greater than 1 disc diameter, congenital toxoplasmosis, and bilateral compromise had more risk of recurrences. Also, environmental and parasite factors such as precipitations, geographical region where the infection is acquired, and more virulent strains confer greater risk of recurrences. Therefore, patients with the above mentioned clinical, environmental, and parasite factors could benefit from using prophylactic therapy.

Identifiants

pubmed: 37011101
doi: 10.1371/journal.pone.0283845
pii: PONE-D-22-34874
pmc: PMC10069780
doi:

Types de publication

Systematic Review Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0283845

Informations de copyright

Copyright: © 2023 Cifuentes-González et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2541
pubmed: 24278490
Br J Ophthalmol. 2008 Sep;92(9):1253-6
pubmed: 18211930
Int Ophthalmol. 2013 Feb;33(1):39-46
pubmed: 23053769
Acta Ophthalmol. 2013 Jun;91(4):e311-4
pubmed: 23336844
Prog Retin Eye Res. 2014 Mar;39:77-106
pubmed: 24412517
Int Ophthalmol. 2017 Jun;37(3):559-563
pubmed: 27480335
Ocul Immunol Inflamm. 2020;28(2):249-255
pubmed: 30806556
Ophthalmology. 2011 Jan;118(1):134-41
pubmed: 20708269
Ophthalmology. 2002 May;109(5):869-78
pubmed: 11986090
Emerg Infect Dis. 2020 Nov;26(12):
pubmed: 33219657
Invest Ophthalmol Vis Sci. 2008 May;49(5):1979-82
pubmed: 18436829
Br J Ophthalmol. 2016 Feb;100(2):195-9
pubmed: 26163541
Exp Eye Res. 2018 Dec;177:104-111
pubmed: 30063883
J Fr Ophtalmol. 1997;20(6):418-22
pubmed: 9296037
Arch Ophthalmol. 1966 Jan;75(1):21-31
pubmed: 5900501
Int Ophthalmol. 2020 Apr;40(4):811-821
pubmed: 31792847
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Am J Ophthalmol. 2020 May;213:195-202
pubmed: 31926883
Ophthalmic Epidemiol. 2021 Jun;28(3):258-264
pubmed: 33115293
Arch Ophthalmol. 1969 Apr;81(4):481-93
pubmed: 5777756
Eye (Lond). 2012 May;26(5):723-8
pubmed: 22361847
Ophthalmology. 2003 May;110(5):926-31; quiz 931-2
pubmed: 12750091
Pediatrics. 2004 Jun;113(6):1567-72
pubmed: 15173475
J Fr Ophtalmol. 1989;12(3):161-5
pubmed: 2695556
Med Sci Monit. 2015 Feb 23;21:582-4
pubmed: 25703198
Sci Rep. 2022 Jan 21;12(1):1156
pubmed: 35064148
Eur J Ophthalmol. 2009 Sep-Oct;19(5):824-30
pubmed: 19787604
Am J Ophthalmol. 2015 Jun;159(6):1002-1012.e2
pubmed: 25743338
Sci Rep. 2016 Nov 09;6:36632
pubmed: 27827450
Cytokine. 2014 Jul;68(1):23-31
pubmed: 24787053
Br J Ophthalmol. 2008 Jul;92(7):986-8
pubmed: 18577652
PLoS One. 2019 Feb 12;14(2):e0211627
pubmed: 30753197
Klin Monbl Augenheilkd. 2005 Sep;222(9):721-7
pubmed: 16175482
Microbes Infect. 2006 Aug;8(9-10):2333-40
pubmed: 16938480
Br J Ophthalmol. 2007 Feb;91(2):233-6
pubmed: 16987904
Int J Parasitol. 2014 Feb;44(2):99-107
pubmed: 24200675
Am J Ophthalmol. 2002 Jul;134(1):41-6
pubmed: 12095806
J Fr Ophtalmol. 2019 Oct;42(8):900-906
pubmed: 31248609
Ophthalmologica. 2013;229(3):173-8
pubmed: 23548496
Am J Ophthalmol. 1999 Oct;128(4):421-5
pubmed: 10577582
Ophthalmology. 2000 Jan;107(1):36-40
pubmed: 10647716
Mem Inst Oswaldo Cruz. 2009 Mar;104(2):351-7
pubmed: 19430663
Am J Ophthalmol. 1993 Apr 15;115(4):517-23
pubmed: 8470726
Br J Ophthalmol. 2009 Aug;93(8):1001-4
pubmed: 19429576
Am J Ophthalmol. 2008 Jun;145(6):1007-1013
pubmed: 18343351
Sci Rep. 2021 Feb 4;11(1):3137
pubmed: 33542439
Am J Ophthalmol. 1997 Jan;123(1):1-16
pubmed: 9186091
Eye (Lond). 2009 May;23(5):1090-3
pubmed: 18617902
PLoS Negl Trop Dis. 2016 Aug 19;10(8):e0004892
pubmed: 27542116
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Int Ophthalmol Clin. 2022 Apr 1;62(2):231-250
pubmed: 35325921
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Am J Ophthalmol. 2002 Apr;133(4):506-15
pubmed: 11931784
Ophthalmology. 2008 Mar;115(3):553-559.e8
pubmed: 17825418
Int Ophthalmol. 2005 Dec;26(6):221-8
pubmed: 17318320
Pediatr Infect Dis J. 2021 Jan;40(1):e21-e27
pubmed: 33060522
Sci Rep. 2021 Feb 9;11(1):3420
pubmed: 33564078
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Am J Ophthalmol. 2002 Jul;134(1):34-40
pubmed: 12095805
Br J Ophthalmol. 2011 Mar;95(3):396-400
pubmed: 20601663
Parasitol Int. 2013 Jun;62(3):272-5
pubmed: 23485566
Ocul Immunol Inflamm. 2022 Apr 3;30(3):560-569
pubmed: 34242103
J Fr Ophtalmol. 1987;10(1):15-23
pubmed: 3598056
Am J Ophthalmol. 1992 Aug 15;114(2):130-5
pubmed: 1322640
Ocul Immunol Inflamm. 2015 Jun;23(3):246-7
pubmed: 25325434
J Curr Ophthalmol. 2016 Dec 28;29(2):120-125
pubmed: 28626822
Parasite. 2013;20:44
pubmed: 24225023
PLoS Negl Trop Dis. 2016 May 02;10(5):e0004685
pubmed: 27136081
Caries Res. 2018;52(3):230-245
pubmed: 29353283
Am J Ophthalmol. 2007 Nov;144(5):648-653
pubmed: 17854757
Retina. 2015 Apr;35(4):809-19
pubmed: 25299969
J Infect Dis. 2013 Nov 1;208(9):1520-8
pubmed: 23878321
Eur J Ophthalmol. 2013 Sep-Oct;23(5):705-17
pubmed: 23661536
Ophthalmology. 2005 Nov;112(11):1876-82
pubmed: 16171866
Ophthalmology. 2002 Jan;109(1):41-5
pubmed: 11772577
Br J Ophthalmol. 2014 Sep;98(9):1218-20
pubmed: 24820044
Klin Mikrobiol Infekc Lek. 2014 Dec;20(4):112-5
pubmed: 25702053
Eur J Ophthalmol. 2011 Nov-Dec;21(6):811-9
pubmed: 21374556
Ocul Immunol Inflamm. 2018;26(8):1289-1296
pubmed: 29020481
Ophthalmologica. 1996;210(2):90-4
pubmed: 9148260

Auteurs

Carlos Cifuentes-González (C)

Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.

William Rojas-Carabali (W)

Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.

Álvaro Olate Pérez (ÁO)

Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.

Érika Carvalho (É)

Clinical Research Laboratory of Infectious Diseases in Ophthalmogy, National Institute of Infectious Disease, INI-Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.

Felipe Valenzuela (F)

Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.

Lucía Miguel-Escuder (L)

Hospital Clinic of Barcelona, Clinic Institute of Ophthalmology, University of Barcelona, Barcelona, Spain.

María Soledad Ormaechea (MS)

Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.
Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.

Milagros Heredia (M)

Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.
Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.

Pablo Baquero-Ospina (P)

Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes" Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico.

Alfredo Adan (A)

Hospital Clinic of Barcelona, Clinic Institute of Ophthalmology, University of Barcelona, Barcelona, Spain.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Andre Curi (A)

Clinical Research Laboratory of Infectious Diseases in Ophthalmogy, National Institute of Infectious Disease, INI-Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Ariel Schlaen (A)

Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.
Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Cristhian Alejandro Urzua (CA)

Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).
Faculty of Medicine, Clinica Alemana-Universidad del Desarrollo, Santiago, Chile.

Cristóbal Couto (C)

Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Lourdes Arellanes (L)

Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes" Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Alejandra de-la-Torre (A)

Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Red de Investigación en Inmunología Ocular de Latinoamérica (RIOLAT).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH